UBS Group AG
- SEC CIK
- 0001610520
- Latest filing
- Aug 13, 2026
EFTR holding history
eFFECTOR Therapeutics, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
EFTR overviewAll 13F holders of EFTRFull Q2 2026 holdings
- Shares (Q3 2024)
- 0
- Sold out in Q3 2024
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 8
- Since Q4 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q3 2024 | 0 | $0 | 0.0% | −61,667−100.0% | Sold out | Holders |
| Q2 2024 | 61,667 | $17.9K | <0.1% | +61,667 | New | Holders |
| Q1 2024 | 0 | $0 | 0.0% | −364−100.0% | Sold outConverted for a 1-for-25 split | Holders |
| Q4 2023 | 9,092 | $4.25K | <0.1% | −782−7.9% | Reduced | Holders |
| Q3 2023 | 9,874 | $5.92K | <0.1% | +9,874 | New | Holders |
| Q2 2023 | 0 | $0 | 0.0% | −21,414−100.0% | Sold out | Holders |
| Q1 2023 | 21,414 | $7.56K | <0.1% | −4,849−18.5% | Reduced | Holders |
| Q4 2022 | 26,263 | $11.3K | <0.1% | +9,705+58.6% | Added | Holders |
| Q3 2022 | 16,558 | $9.00K | <0.1% | +16,558 | New | Holders |
| Q2 2022 | 0 | $0 | 0.0% | −141−100.0% | Sold out | Holders |
| Q1 2022 | 141 | $1.00K | <0.1% | −2,260−94.1% | Reduced | Holders |
| Q4 2021 | 2,401 | $20.0K | <0.1% | +2,401 | New | Holders |